Skip to main content
Terug
INSP logo

Inspire Medical Systems, Inc.

Datakwaliteit: 100%
Oversold
INSP
NYSE Healthcare Medical - Devices
€ 52,16
▼ € 1,56 (-2,90%)
Marktkapitalisatie: 1,52B
Dagbereik
€ 51,95 € 54,00
52-Weeksbereik
€ 51,95 € 172,95
Volume
779.960
50D / 200D Gem.
€ 70,58 / € 94,45
Vorige Slotkoers
€ 53,72

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 10,4 0,4
P/B 1,9 2,9
ROE % 19,8 3,8
Net Margin % 16,0 3,9
Rev Growth 5Y % 40,6 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 40,60% annually over 5 years — strong growth
Earnings grew 171,77% over the past year
ROE of 19,77% — decent returns on equity
Net margin of 15,95% shows strong profitability
Debt/Equity of 0,04 — conservative balance sheet
Generating 78,48M in free cash flow

Groei

Revenue Growth (5Y)
40,60%
Revenue (1Y)13,60%
Earnings (1Y)171,77%
FCF Growth (3Y)775,43%

Kwaliteit

Return on Equity
19,77%
ROIC4,70%
Net Margin15,95%
Op. Margin5,59%

Veiligheid

Debt / Equity
0,04
Current Ratio6,08
Interest Coverage371,93

Waardering

P/E Ratio
10,42
P/B Ratio1,94
EV/EBITDA28,32
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13,60% Revenue Growth (3Y) 20,82%
Earnings Growth (1Y) 171,77% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 40,60% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 911,98M Net Income (TTM) 145,42M
ROE 19,77% ROA 16,03%
Gross Margin 85,39% Operating Margin 5,59%
Net Margin 15,95% Free Cash Flow (TTM) 78,48M
ROIC 4,70% FCF Growth (3Y) 775,43%
Safety
Debt / Equity 0,04 Current Ratio 6,08
Interest Coverage 371,93 Dividend Yield 0,00%
Valuation
P/E Ratio 10,42 P/B Ratio 1,94
P/S Ratio 1,66 PEG Ratio 0,11
EV/EBITDA 28,32 Dividend Yield 0,00%
Market Cap 1,52B Enterprise Value 1,44B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 911,98M 802,80M 624,80M 407,86M 233,39M
Net Income 145,42M 53,51M -21,15M -44,88M -42,04M
EPS (Diluted) 4,89 1,75 -0,72 -1,60 -1,54
Gross Profit 778,76M 679,82M 528,22M 341,74M 200,12M
Operating Income 50,95M 36,08M -40,27M -47,59M -39,85M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 907,32M 808,38M 676,81M 564,88M 295,08M
Total Liabilities 126,16M 118,69M 104,30M 68,87M 66,04M
Shareholders' Equity 781,16M 689,70M 572,51M 496,01M 229,05M
Total Debt 32,16M 31,79M 24,85M 16,41M 34,10M
Cash & Equivalents 104,81M 150,15M 185,54M 441,59M 214,47M
Current Assets 583,65M 630,81M 593,74M 530,03M 268,54M
Current Liabilities 96,06M 88,50M 78,11M 61,19M 41,31M

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Capital Light Compounder
#176 of 213
26
Custom Contrarian Investing (David Dreman)
#422 of 658
19
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#173 of 326
50
Custom Lower Risk
#105 of 136
37

Recente Activiteit

Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026